Cyclin-Dependent Kinase 1 (CDK1) is Co-Expressed with CDCA5: Their Functions in Gastric Cancer Cell Line MGC-803

Zhigang Huang*
Shizhuo Zhang*
Jinlin Du
Xing Zhang
Weijian Zhang
Zhaowei Huang
Ping Ouyang

* Zhigang Huang and Shizhuo Zhang are equally contributed to this work and considered to be co-first authors

Background: Gastric cancer (GC) is a worldwide malignancy and the molecular mechanism of the GC carcinogenesis has not been fully elucidated. Our previous study suggested CDCA5 played a role in GC development via regulating cell proliferation, migration, and apoptosis in GC cells.

Material/Methods: Here, we first carried out bioinformatics analysis and found cyclin-dependent kinase 1 (CDK1) was possibly as-sociated with CDCA5 using STRING. Then, the expression levels of CDK1 and CDCA5 in cancer tissues were es-timated through Oncomine and The Cancer Genome Atlas (TCGA) database. After that, functional experiments were exerted to detect the association of CDK1 and CDCA5. Finally, cell proliferation assay, colon formation assay, cell scratch assay, transwell migration and invasion assays were applied to explore the roles of CDK1 and CDCA5 in GC cells MGC-803.

Results: CDK1 and CDCA5 were both upregulated and co-expressed in GC tissues. The expression of CDK1 and CDCA5 in MGC-803 was positively related. CDK1 or CDCA5 inhibition can suppress the proliferation, colon formation, migration, and invasion abilities of GC cells.

Conclusions: Co-expression of CDK1 and CDCA5 might confer cell proliferation, migration, and invasion abilities in GC cells, and this can provide some clues for further therapies of gastric tumors.

MeSH Keywords: CDC2 Protein Kinase • Cell Cycle Proteins • Cell Migration Assays • Cell Proliferation • Neoplasm Invasiveness • Stomach Neoplasms

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/923664
Background

Gastric cancer (GC) is a digestive tract malignant tumor and ranks the third cause among cancer-associated deaths in China [1]. Though many advances have been made in GC treatment, the 5-year survival rate is still low due to low early diagnosis rate, extensive invasion, and high lymphatic metastasis rate [2]. Therefore, studies about the molecular mechanisms in GC progression is still needed for better therapies.

CDCA5 (also named Sororin and with a full name of cell division cycle associated 5) is a conserved protein with 252 amino acids and the molecular weight is ~27.6 kDa. It plays a role in mitosis stabilizing cohesion complex association with chromatin [3]. Recently, CDCA5 has been found to be aberrantly expressed in many tumor tissues and associated with poor prognosis in some cancer types [4–6]. Our previous research demonstrated CDCA5 overexpression enhanced cell proliferation and migration, while CDCA5 inhibition can arrest cell cycle in G2/M phase in GC cells MGC-803 [7]. In order to find possible interaction proteins of CDCA5, we used the online free functional protein association network STRING (https://string-db.org/cgi/input.pl), and found CDK1, AURKB, and BIRC5 may interact with CDCA5. Then, we searched the gene expression levels of these genes using the Oncomine (https://www.oncomine.org/) and The Cancer Genome Atlas (TCGA) database (https://www.cancer.gov/). The results showed CDK1 was abnormally expressed in cancer tissues. CDK1 is a family member of the cyclin-dependent kinases (CDKs) which are important drivers in cell cycle regulation [8]. Research showed CDK1 was an essential regulator for cell cycle at G1/S and G2/M checkpoints [9,10] and it can also be regulated by certain microRNAs to inhibit tumor cell proliferation in cancers [11,12]. Until now, the role of CDK1 in GC is not clear. Herein, given that CDK1 may interact with CDCA5 in GC, we aimed to explore the relationship between CDCA5 and CDK1 and their roles in MGC-803 looking to identify potential new targets in GC treatment.

Material and Methods

Bioinformatics analysis

STRING is a well-known protein-protein interaction database [13]. We first input CDCA5 and found CDK1 may be a potential interaction protein using STRING. Then, we analyzed the mRNA expression levels of CDCA5 and found CDK1 in the TCGA [14] and Genotype-Tissue Expression (GTEx) projects on the GEPIA website (http://gepia.cancer-pku.cn/) which possesses more than 9000 tumor tissues and 8000 normal tissues [15]. Next, based on the gene expression data, overall survival (OS) or disease-free survival (DFS) analysis were performed using Log-rank test for hypothesis test. Co-expression of CDK1 with CDCA5 in GC samples was also assessed from the Oncomine dataset under standardized instructions on the website [16–19].

Small interfering RNAs and transfection

To knockdown CDCA5 and CDK1 in GC cell line, specific small interfering RNAs (siRNA) against CDCA5 and CDK1, and scramble siRNA not targeting any annotated human genes (control) were designed and purchased from Shanghai Genechem (Genechem, Shanghai, China). The siRNAs against CDCA5 were as follows: si-CDCA5, sense: 5’-CGGAAAGUUUCCGCGGUA-3’ and antisense: 5’-UACCGGAGGAAACUUCGG-3’.

For transfections, cells were first seeded onto 6-well plates. When the cell confluency got about 75%, the indicated siRNAs were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) under the instruction manual.

RNA extraction and real-time quantitative polymerase chain reaction (RT-qPCR)

After the transfection, the cells were harvested 24 hours later and the total RNAs were extracted by TRIzol (Invitrogen, USA). The first-strand cDNA was synthesized by reverse transcription using 250 ng total RNAs in a volume of 10.0 µL using a first strand cDNA synthesis kit (Roche, Basel, Switzerland). Then the cDNA was diluted in sterile water and the quantitative real-time polymerase chain reaction (RT-qPCR) was carried out with a mixture as follows: 1.0 µL cDNA, 0.4 µL forward primer, 0.4 µL reverse primer, 5.0 µL SYBR® Select Master mix (Roche, Basel, Switzerland) and 3.2 µL deionized water. The amplification was exerted using a PikoReal™ Real-Time PCR system (Thermo Fisher Scientific, Waltham, MA, USA). The primers were obtained by Shanghai Generay Co., Ltd. (Shanghai, China) and the sequences were as follows:

CDCA5-f 5’-CGTAAGAAGAAGAAAATGCC-3’ and CDCA5-r 5’-ACAGGACAGGAGGGAGAG-3’;

CDK1-f 5’-GGATGTGCTTATGCAGGATTCC-3’ and CDK1-r 5’-ACAGGACAGGAGGGAGAG-3’;

The effects of CDCA5 and CDK1 in GC cells MGC-803

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) Huang Z. et al.:

© Med Sci Monit, 2020; 26: e923664
CDK1-r 5'-CATGTACTGACCCAGGGGATAG-3';
β-actin-f 5'-GGGAAATCGTTGCTGACATTACG-3' and
β-actin-r 5'-GACAGAAGGGGCTGAGGTG-3'.
β-actin was used as an endogenous control. The experiments were exerted in triplicate and every experiment was repeated 3 times independently. The 2−ΔΔCT method was applied for data analysis [21].

Western blot

Cells were washed 3 times with cold, sterile phosphate-buffered saline (PBS), and then lysed by addition of 1 mL of radioimmunoprecipitation assay (RIPA) lysis buffer (Solarbio, Beijing, China) supplemented with protease inhibitor cocktail (Sigma, St. Louis, MO, USA). Cell lysates were collected into tubes and centrifuged at 12 000 g for 15 minutes at 4°C. The supernatants and protein loading buffer (SDS-PAGE gel, CWBio, Beijing, China) were mixed at a ratio of 4:1 according to the instructions and then divided into 2 aliquots. One aliquot was fractionated by SDS-PAGE, and the other was stored at -80°C. All the western blotting procedures were performed according to the manuals. In this study, the primary antibodies used were as follows: a rabbit anti-human CDCAS (ab192237, 1:1000, Abcam, Cambridge, MA, USA), a rabbit anti-human CDK1 antibody (ab32094, 1:1500, Abcam, Cambridge, MA, USA), a rabbit anti-human β-actin antibody (ab8227, 1:100; Abcam, Cambridge, MA, USA). An HRP-labeled goat anti-rabbit antibody (A0208, 1:1000, Beyotime, China) was used as the second antibody. The band signals were detected using chemiluminescence (Millipore, MA, USA) by infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA). The target protein was normalized to β-actin through a comparison of the gray scale values, and the analysis was performed by Quantity One (version 4.6.2).

Cell proliferation experiment

About 24 hours after the transfection, the cells were harvested and re-cultured in a 96-well microplate with about 3000 cells/well. Each group had 5-wells. After 24 hours, each well was added with 100 μL mixture containing 10 μL CCK-8 (Cell Counting Kit-8, Dojindo Laboratories, Kumamoto, Japan) and 90 μL RPMI-1640, and the cells were continued cultured for 3 hours at 37°C with 5% CO₂. The value of CCK-8 was measured at 450 nm by microplate reader (Thermo Fisher Scientific, USA) at the time point of 24, 48, and 72 hours. The experiments were performed for 3 independent times with each had 3 replicates.

Colon formation experiment

About 24 hours after the transfection, the cells were collected and re-cultured in 6-well plates with about 1.0×10⁴ cells/well. The medium was switched to fresh Dulbecco’s Modified Eagle Medium (DMEM) medium with 10% FBS every 72 hours. Generally, 1–2 weeks later, the cells were fixed by pre-cold methanol for 20 minutes and then stained with 0.2% purple crystal at 25°C for 25–35 minutes. For the cell number counting, the colonies including more than 50 cells were included. The experiments were performed for 3 independent times with each had 3 replicates.

Cell scratch test

Forty-eight hours after cell transfection, when the confluence of the cells in the 6-well plate reached 100%, a single scratch wound at the same position in each well was generated by scratching the cell monolayer with a 10 μL sterile pipette tip. Then, the remaining cells washed 3 times with use fetal bovine serum (FBS)-free 1640 culture basic culture. Then the cells were filled with RPMI-1640 medium contained 2.5% FBS and incubated with 5% CO₂ at 37°C. Spontaneous cellular migration of the cells at the edge of the scratch was observed and photographed at time 0, 24, and 48 hours using a light microscope (Olympus BX41, Olympus Corporation, Tokyo, Japan). The experiments were performed for 3 independent times with each had 3 replicates.

Transwell migration experiment

Twenty-four hours after the transfection, the cells were collected and re-suspended with blank RPMI-1640 medium. Then 200 μL suspensions (about 2.5×10⁵ cells) were plated on the upper chamber of a Matrigel coated Transwell (200 μL/well), and the lower chambers contained 600 μL RPMI-1640 supplemented with 10% FBS. The chambers were placed in an incubator with 5% CO₂ at 37°C. After 48 hours, the cells on the lower chambers were fixed with cold methanol for about 30 minutes, next the cells were stained with 0.1% crystal violet for about 15 minutes at 25°C. Finally, 5 random fields were photographed and counted using a light microscope. The experiments were performed for 3 independent times with each had 3 replicates.

Transwell invasion assay

The Matrigel matrix (Corning, Inc., Corning, NY, USA) and the RPMI-1640 medium without fetal bovine serum were mixed in a ratio of 1:5, and then 60 μL above mixture was added into the upper chamber of Transwell for 4 hours at 37°C. Next, the Transwell upper chamber were added with 200 μL cell suspension including about 2.5×10⁵ cells, and the lower chamber were added with 600 μL RPMI-1640 medium supplemented with 10% FBS. After that, the chambers were placed at 37°C with 5% CO₂. Forty-eight hours after the incubation, the non-migrating cells were gently removed from the upper chamber with a cotton swab, and the remaining fixed and stained steps...
were similar with that in the aforementioned migration assay. The experiments were performed for 3 independent times with each had 3 replicates.

Statistical analysis

The data in this study were analyzed by SPSS 25.0 and GraphPad Prism 8. The data were indicated as the mean±standard deviation (SD). Independent sample t-test was applied for the comparison between 2 groups, and one-way ANOVA was exerted for comparisons between multiple groups. \( P<0.05 \) was thought to be statistically significant.

Results

Bioinformatics analysis suggested co-expression of CDCA5 and CDK1 in GC tissues

In the functional protein association network constructed by STRING, the interaction between CDCA5 and CDK1 was evaluated from 5 aspects: genomic context predictions, high-throughput laboratory experiments, co-expression, automated text mining, and previous knowledge in databases. The results showed a high score between the association of CDCA5 and CDK1 (Figure 1A, 1B). Data from the TCGA expression data suggested a positive correlation between CDCA5 and CDK1 expression using a pairwise gene expression correlation analysis (Figure 1C). Co-expression analysis of the clinical specimens from Oncomine database demonstrated CDCA5 was highly correlated with CDK1 in GC (Figure 2). These results confirmed an association of CDCA5 and CDK1.

Then, the mRNA expression levels of CDCA5 and CDK1 were analyzed from TCGA and GTEx project containing a total of 9736 tumor samples and 8726 normal samples. The result presented both CDCA5 and CDK1 expressions were upregulated in most tumor tissues including GC compared with the matched normal tissues (Figure 3), which suggested CDCA5 and CDK1 had a similar expression pattern in GC tissues.

The mRNA expression levels of CDCA5 and CDK1 in 3 GC lines and selection of efficient siRNA fragments against CDCA5 and CDK1

The relative mRNA expression levels of CDCA5 and CDK1 in 3 GC cell lines SGC-7901, BGC-823 and MGC-803 were tested by RT-qPCR, respectively. Figure 4A showed CDCA5 mRNA was the highest in MGC-803. Interesting, CDK1 had a similar expression pattern as CDCA5 in 3 cell lines (Figure 4B). Therefore, MGC-803 was chosen for the cell line in the following experiments.

To explore the function of CDCA5 and CDK1, we applied siRNA interfering method to knockdown gene expression and investigate the effects on GC cell. For the CDCA5 inhibition experiments, compared with si-NC control group (transfecting siRNAs
Figure 2. Co-expression analysis of CDCA5 and CDK1. Co-expression analysis of CDCA5 and CDK1 in clinical specimens of gastric cancer showed high correlation between the 2. (A) R=0.752, n=132; (B) R=0.715, n=90; (C) R=0.850, n=43; (D) R=0.632, n=27.
The effects of CDCAS and CDK1 in GC cells MGC-803

© Med Sci Monit, 2020; 26: e923664

not targeting any gene), the mRNA and protein expression levels of CDCA5 in si-CDCA5 group (transfecting siRNAs targeting CDCA5) were significantly decreased (Figure 4C, 4D). In detail, the mRNA expression level was markedly reduced by 83.3% (Figure 4C), and the protein level was significantly reduced by 30.2% (Figure 4D).

For the CDK1 inhibition experiments, there were 3 siRNA fragments (named si-CDK1-1, si-CDK1-2, and si-CDK1-3) designed, and the RT-qPCR results showed all the 3 were efficient to knockdown CDK1, among which, the most efficient one was si-CDK1-2 (Figure 4E). In the group transfecting si-CDK1-2, compared with the control, the mRNA level was significantly reduced by 88.5% (Figure 4E), while the CDK1 protein level reduced by 40.8% (Figure 4F). Thus, the fragment of si-CDK1-2 was selected for subsequent experiments.

The expressions of CDCA5 and CDK1 in MGC-803 were positively related

To explore the relationship between CDCA5 and CDK1, we first detected the expression change of CDK1 after transfecting si-CDCA5 in MGC-803. CDCA5 protein has 252 amino acids with the molecular weight of about 27 kDa. CDK1 protein has 297 amino acids with the molecular weight of about 34 kDa. Compared with that of the si-NC group, the mRNA of CDK1 was significantly reduced by 83.5% (Figure 5A) and the protein of CDK1 reduced about 28% (Figure 5B). Then we detected the mRNA and protein expression levels of CDCA5 after transfecting si-CDK1 in MGC-803 cells. Compared with that of the si-NC group, the mRNA of CDCA5 was significantly reduced by 58% (Figure 5C) and the protein of CDK1 reduced by 20% (Figure 5C) and the protein level was significantly reduced by 83.3% (Figure 5D). These results confirmed a correlation between CDCA5 and CDK1 in GC cells.

Effects of CDCA5 and CDK1 in MGC-803 cells

To determine the effects of CDCA5 and CDK1 in GC cells, CDCA5 and CDK1 were knocked down by siRNA interfering, respectively. CCK8 assay and colony formation experiments were performed to assess the proliferation ability; cell scratch assay and Transwell migration experiments were carried out to detect the migration ability; and Transwell assay was applied to detect the invasion ability.

As a result, the CCK-8 assay and the plate colony formation experiment showed that both CDCA5 inhibition and CDK1 inhibition reduced the proliferation and colony forming ability of MGC-803 cells (Figure 6A–6C). Cell scraping experiments suggested both CDCA5 inhibition and CDK1 inhibition reduced cell migration ability of MGC-803 cells (Figure 6A, 6B). Similarly, the results of Transwell cell migration analysis indicated that CDCA5 inhibition or CDK1 inhibition suppressed the migration of MGC-803 cells (Figure 6A–6C). These results confirmed a correlation between CDCA5 and CDK1 in GC cells.

Figure 3. Upregulation of CDCA5 and CDK1 in gastric cancer. (A) The gene expression profile of CDCA5 across all tumor samples and matched normal tissues, based on the expression of CDCA5 from the The Cancer Genome Atlas (TCGA) various types of cancer research cohort data sets, generated by the GEPIA website, the height of bar represents the median expression of certain tumor type or normal tissue. (B) The gene expression profile of CDK1 across all tumor samples and paired normal tissues. (C) Analysis of TCGA gastric cancer tissue data (n=408) and match TCGA normal and GTEx data (n=211) through the GEPIA website, to obtain CDCA5 expression levels. (D) Analysis of TCGA gastric cancer tissue data (n=408) and match TCGA normal and GTEx data (n=211) through the GEPIA website, to obtain CDK1 expression levels (Log2FC=1, P-value=0.01).
ability of MGC-803 cells (Figure 7C, 7D). The Transwell cell invasion tests also suggested that CDCA5 inhibition or CDK1 inhibition reduced the cell invasion capacity of MGC-803 cells (Figure 8A, 8B). These results showed CDK1 played a similar role as CDCA5 in GC cell progression.

Discussion

In this study, we first found the association of CDK1 and CDCA5 using STRING, Oncomine and TCGA database. Then we performed functional experiments to evaluate their relationship in
gastric cells, and the results implicated the two proteins were positively regulated with each other, both can increase cell proliferation, migration, and invasion abilities of GC MGC-803 cells. The CDCA5 protein is also named Sororin, which is a key regulator in sister chromatid condensation [22,23]. Recently, CDCA5 has also been found to be upregulated in many human tumor cases and its transcriptional level is significantly correlated with high pathological stage and overall survival rate, such as lung cancer [5], liver cancer [24], and oral squamous cell carcinoma [25]. In our previous study, we demonstrated the role of CDCA5 in GC cell proliferation, migration, and cell cycle changes [7]. Cyclin-dependent kinases (CDKs) are important drivers of cell cycle regulation and are thought to be potential targets for cancer therapy [26]. Among which CDK1 is a key regulator at G2/M checkpoint during the cell cycle.

Knockdown of CDK1 had been proven to induce G2/M blockade and the uncontrolled mitotic activity may enhance genomic instability, which may lead to abnormal proliferation of malignant cells [10]. In fact, upregulation of CDK1 was often been observed in many advanced tumors [27–29] and dysregulation of CDK1 contributed to the failure of traditional chemotherapy drugs to eradicate cancer [30]. All these results suggested CDCA5 and CDK1 were cancer-related genes.

CDCA5 and CDK1 were positively related with each other and had similar roles in GC cell progression. Through knockdown assay by siRNA interfering, we found the mRNA and protein expression levels of CDCA5 were downregulated owing to CDK1 inhibition, and the same expression patterns were observed about the expression of CDK1 response to CDCA5 inhibition. Our results were consistent with Shen et al.’s study. They had

**Figure 5.** Relationship between CDK1 expression and CDCA5 expression. To explore the relationship between CDK1 and CDCA5, cells were knocked down one gene and checked the mRNA and protein expression level changes of the other gene. (A) Relative mRNA expression levels of CDK1 in cells transfected with si-NC and si-CDCA5 by quantitative real-time polymerase chain reaction (RT-qPCR) (** P<0.01). (B) Relative protein expression levels of CDK1 in cells transfected with si-NC and si-CDCA5 by western blot (* P<0.05). (C) Relative mRNA expression levels of CDCA5 in cells transfected with si-NC and si-CDK1 by RT-qPCR (* P<0.05). (D) Relative protein expression levels of CDCA5 in cells transfected with si-NC and si-CDK1 by western blot (* P<0.05).
also analyzed the relationship of CDC5 and CDK1 in hepatocellular carcinoma and found CDC5 inhibition suppressed cell survival as well as cell cycle and cell apoptosis by downregulation of CDK1 and CyclinB1. Moreover, CDC5 overexpression upregulated the expression of CDK1 and CyclinB1 [24]. Our study suggested CDK1 inhibition or CDC5 inhibition can suppress GC cell proliferation, migration, and invasion. Zhang et al. had also analyzed the function of CDC5 inhibition in GC cells MKN45 and SGC7901, and they found the cell proliferation, migration, and invasion abilities were reduced, which were similar results with ours in MGC-803 cells [30]. Gao et al. investigated the effect of CDK1 in GC cells SGC-7901, and discovered downregulation of CDK1 inhibited the cell proliferation as in our study [31]. To our knowledge, this was the first comprehensively analysis of the proliferation, migration, and invasion abilities of CDK1 inhibition in GC cells.

CDCA5 and CDK1 can influence the expression of each other in GC cells, but it seemed that CDK1 had a bigger impact because CDCA5 protein reduced by about 58% (Figure 5D) while CDK1 reduced it by only about 28% (Figure 5B). It may be interpreted that CDCA5 was phosphorylated by CDK1 in GC cells. CDK1 is a protein kinase and the full consensus site for CDK1 phosphorylation is [S/T]Px[K/R] [32]. A previous study speculated that the phosphorylation and dephosphorylation processes of CDCA5 were involved in the regulation of cohesion, which was a necessary process of cell cycle, and the antagonism of a series of kinases such as CDK1 and protein phosphatase 2A played a unique role in this regulation [33,34]. Then, CDCA5 was found to be co-regulated with known cell cycle genes including CDK1 and CYCLINB [35]. Next, CDCA5 phosphorylation during the mitosis process was confirmed and CDK1 was reported to play an important role in the complex mitosis involved in the regulation of CDCA5 protein [36]. Further, Zhang et al. analyzed CDCA5 protein primary structure and identified 3 putative CDK1 phosphorylation sites as S_{21}PTK, S_{75}PRR, and T_{159}PGR by in vitro phosphorylation of CDCA5 by CDK1 using mass spectrometry. Especially, Ser_{21} conferred 70% of the total CDCA5 phosphorylation while Thr_{159} conferred 20%. Thus, they concluded Ser_{21} and Thr_{159} of CDCA5 were CDK1 phosphorylation sites [37]. Based on the previous studies, it can be speculated that CDCA5 was first phosphorylated by CDK1 and then influenced the malignant behaviors in GC cells. However, whether CDCA5 was phosphorylated by CDK1 on Ser_{21} and Thr_{159} or not in MGC-803 cells was not clear because Zhang et al. performed these experiments using HeLa cells, and thus more experiments are needed in the future.
Conclusions

Taken together, our work showed CDK1 and CDCA5 were positively correlated with each other, and both can promote cell proliferation, migration, and invasion in GC cells. CDCA5 and CDK1 may have the potential as diagnostic markers and therapeutic targets in GC therapy.

Conflict of interests

None.
References:

1. Chen W, Zheng R, Baade PD et al: Cancer statistics in China, 2015. Cancer J Clin, 2016; 66(2): 115–32

2. Zheng G, Xiong Y, Xu W et al: A two-microRNA signature as a potential biomarker for early gastric cancer. Oncol Lett, 2014; 7(3): 679–84

3. Zhang N, Pati Q, Sororin is a master regulator of sister chromatid cohesion and separation. Cell Cycle, 2012; 11(11): 2073–83

4. Wang J, Xia C, Pu M et al: Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma. Oncol Rep, 2018; 40(4): 1875–84

5. Nguyen MH, Koinuma J, Ueda K et al: Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung cancerogenesis. Cancer Res, 2010; 70(13): 5337–47

6. Xu T, Ma M, Dai J et al: Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma. Human Pathol, 2018; 75: 137–45

7. Chen T, Huang Z, Tian Y et al: Role of triosephosphate isomerase and downstream functional genes on gastric cancer. Oncol Rep, 2017; 38(3): 1822–32

8. Santamaria D, Barrière C, Cerqueira A et al: Cdk1 is sufficient to drive the mammalian cell cycle. Nature, 2007; 448(7155): 811–15

9. Lohberger B, Leithner A, Stuendl N et al: Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation. BMC Cancer, 2015; 15: 891

10. Syn NL, Lim, Kong LR et al: Pan-CDK inhibition augments cisplatin lethal activity in nasopharyngeal carcinoma cell lines and xenograft models. Signal Transduc Target Ther, 2018; 3: 9

11. Shi Q, Zhou Z, Ye N et al: MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1. Cancer Biomark, 2017; 20(4): 539–46

12. McGuinness BE, Hirota T, Kudo NR et al: Shugoshin prevents dissociation of the cohesion complex, is required for sister chromatid cohesion in vertebrates. Mol Cell, 2005; 18(4): 3208–15

13. Cho JY, Lim JY, Cheong JH et al: Gene expression signature-based prognosis and separation. Cell Cycle, 2012; 11(11): 2073–83

14. Wang J, Xia C, Pu M et al: Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma. Oncol Rep, 2018; 40(4): 1875–84

15. Nishiyama T, Ladurner R, Schmitz J et al: Sororin mediates sister chromatid cohesion by antagonizing Wapl. Cell, 2010; 143(5): 737–49

16. Liu D, Wang H, Li X et al: Experimentation and separation. Cell Cycle, 2012; 11(11): 2073–83

17. Zhang N, Pati Q, Sororin is a master regulator of sister chromatid cohesion and separation. Cell Cycle, 2012; 11(11): 2073–83

18. Forster S, Greschel S, Jons T et al: THBS4, a novel stromal molecule of diffuse-type gastric adenocarcinomas, identified by transcriptome-wide expression profiling. Modern Pathol, 2011; 24(10): 1390–403

19. Wang Q, Wen YG, Li DP et al: Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol, 2012; 29(1): 77–83

20. Huang Z, Lin B, Pan H et al: Gene expression profile analysis of ENO1 knockdown in gastric cancer cell line MGC-803. Oncol Lett, 2019; 17(4): 3881–89

21. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 2001; 25(4): 402–8

22. Rankin S, Ayad NG, Kirschner MW: Sororin, a substrate of the anaphase-promoting complex, is required for sister chromatid cohesion in vertebrates. Mol Cell, 2005; 18(2): 185–200

23. Nishiyama T, Ladurner R, Schmitz J et al: Sororin mediates sister chromatid cohesion by antagonizing Wapl. Cell, 2010; 143(5): 737–49

24. Shen Z, Xu X, Zheng Y et al: CDCA5 regulates proliferation in hepatocellular carcinoma and has potential as a negative prognostic marker. Oncotargets Ther, 2018; 11: 891–901

25. Tokuzen N, Nakashiro K, Tanaka H et al: Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma. Oncotarget, 2016; 7(3): 2343–53

26. Fischer PM, Gianella-Borradori A: CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs, 2003; 12(6): 955–70

27. Pan WX, Chen L, Hong Y et al: EIF3D silencing suppresses renal cell carcinoma tumorigenesis via inducing G2/M arrest through downregulation of Cyclin B1/CDK1 signaling. Int J Oncol, 2016; 48(6): 2580–90

28. Ira G, Pellicioli A, Ballija A et al: DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1. Nature, 2004; 431(7011): 1011–17

29. Thorennoor N, Falejtszova-Vychytalova P, Hombach S et al: Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. Oncotarget, 2016; 7(1): 622–37

30. Zhang Z, Shen M, Zhou G: Upregulation of CDCA5 promotes gastric cancer malignant progression via influencing cyclin E1. Bioch Biophys Res Commun, 2018; 496(2): 482–89

31. Luo S, Gao SY, Li J, Qu XY et al: Downregulation of CDK1 and cyclinB1 expression contributes to oridonin-induced cell cycle arrest at G2/M phase and growth inhibition in SGC-7901 gastric cancer cells. Asian Pac J Cancer Prev, 2014; 15(15): 6437–41

32. Ubersax JA, Woodbury EL, Quang PN et al: Targets of the cyclin-dependent kinase CDK1. Nature, 2003; 425(6960): 859–64

33. Zhang N, Panigrahi AK, Mao Q, Pati D: Interaction of Sororin protein with polo-like kinase 1 mediates resolution of chromosomal arm cohesion. J Biol Chem, 2011; 286(48): 41826–37

34. McGuinness BE, Hirota T, Kudo NR et al: Shugoshin prevents dissociation of cohesion from centromeres during mitosis in vertebrate cells. PLoS Biol, 2005; 3(3): e86

35. Walker MG: Drug target discovery by gene expression analysis: Cell cycle genes. Curr Cancer Drug Targets, 2001; 1(1): 73–83

36. Dreier MR, Bekier ME, Taylor WR: Regulation of Sororin by CDK1-mediated phosphorylation. J Cell Sci, 2011; 114: 2976–87

37. Zhang N, Panigrahi AK, Mao Q, Pati D: Interaction of Sororin protein with polo-like kinase 1 mediates resolution of chromosomal arm cohesion. J Biol Chem, 2011; 286(48): 41826–3.